Related Experiment Videos
In vivo activity of cefodizime
Infection
|January 1, 1992
Summary
Cefodizime demonstrates potent in vivo antibacterial activity, often surpassing in vitro predictions and comparing favorably to other cephems. Its efficacy is linked to favorable pharmacokinetics and synergy with host defenses.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Cefodizime is a cephalosporin antibiotic.
- Understanding its in vivo efficacy is crucial for clinical application.
Purpose of the Study:
- To evaluate the in vivo antibacterial activity of cefodizime.
- To compare its efficacy with other cephalosporins.
- To explore the reasons behind its observed therapeutic effects.
Main Methods:
- Experimental infection models in various animal species (mice, rats, rabbits).
- Assessment of cefodizime's efficacy in systemic, respiratory, and urinary tract infections.
- Comparison of in vivo efficacy with in vitro susceptibility data.
Main Results:
- Cefodizime exhibited high in vivo antibacterial activity across multiple infection models.
- Therapeutic efficacy often exceeded in vitro expectations and compared favorably to other cephems.
- Findings attributed to superior pharmacokinetics (long half-life, tissue penetration) and synergy with host defenses.
Conclusions:
- Cefodizime possesses significant in vivo antibacterial properties.
- Its pharmacokinetic profile and interaction with host immunity contribute to its effectiveness.
- Once-daily dosing of 1-2g is likely effective against common respiratory and urinary pathogens based on MIC90 and human pharmacokinetics.